Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.

Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U.

Ann Intern Med. 2019 Sep 24. doi: 10.7326/M18-3633. [Epub ahead of print]

PMID:
31546257
2.

Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.

Lietz AP, Weaver DT, Melamed A, Rauh-Hain JA, Wright JD, Wright AA, Knudsen AB, Pandharipande PV.

PLoS One. 2019 Sep 20;14(9):e0222828. doi: 10.1371/journal.pone.0222828. eCollection 2019.

3.

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I.

PLoS One. 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019.

4.

Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States.

Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, Wakeman SE, Freedberg KA, Raphel TJ, Knudsen AB, Pandharipande PV, Chhatwal J.

JAMA Netw Open. 2019 Feb 1;2(2):e187621. doi: 10.1001/jamanetworkopen.2018.7621.

5.

Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach.

Weaver DT, Lietz AP, Mercaldo SF, Peters MLB, Hur C, Kong CY, Wolpin BM, Megibow AJ, Berland LL, Knudsen AB, Pandharipande PV.

AJR Am J Roentgenol. 2019 Mar;212(3):596-601. doi: 10.2214/AJR.18.20180. Epub 2019 Jan 8.

PMID:
30620679
6.

Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2974-2985. doi: 10.1002/cncr.31542. Epub 2018 May 30.

7.

Patient Navigation to Improve Cancer Screening in Underserved Populations: Reported Experiences, Opportunities, and Challenges.

Neal CD, Weaver DT, Raphel TJ, Lietz AP, Flores EJ, Percac-Lima S, Knudsen AB, Pandharipande PV.

J Am Coll Radiol. 2018 Nov;15(11):1565-1572. doi: 10.1016/j.jacr.2018.03.001. Epub 2018 Apr 21. Review.

PMID:
29685346
8.

Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.

Weaver DT, Raphel TJ, Melamed A, Rauh-Hain JA, Schorge JO, Knudsen AB, Pandharipande PV.

Gynecol Oncol. 2018 May;149(2):256-262. doi: 10.1016/j.ygyno.2018.02.007. Epub 2018 Mar 1.

PMID:
29486993
9.

Imaging Follow-up of Low-Risk Incidental Pancreas and Kidney Findings: Effects of Patient Age and Comorbidity on Projected Life Expectancy.

Raphel TJ, Weaver DT, Berland LL, Herts BR, Megibow AJ, Knudsen AB, Pandharipande PV.

Radiology. 2018 May;287(2):504-514. doi: 10.1148/radiol.2018171701. Epub 2018 Feb 5.

PMID:
29401040
10.

Composition and adaptation of human myotendinous junction and neighboring muscle fibers to heavy resistance training.

Jakobsen JR, Mackey AL, Knudsen AB, Koch M, Kjaer M, Krogsgaard MR.

Scand J Med Sci Sports. 2017 Dec;27(12):1547-1559. doi: 10.1111/sms.12794. Epub 2016 Oct 26.

PMID:
27781307
11.

A restricted look at CRC screening: not considering annual stool testing as an option.

Kuntz KM, Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Berger BM, Levin B.

Am J Manag Care. 2016 Jul 1;22(7):e270-4. No abstract available.

12.

Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM.

JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828.

13.

Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications.

Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Med Decis Making. 2016 Jul;36(5):604-14. doi: 10.1177/0272989X15622642. Epub 2016 Jan 8.

14.

Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening.

Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC.

Med Care. 2015 Jul;53(7):630-8. doi: 10.1097/MLR.0000000000000380.

15.

Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer [Internet].

Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Dec 20.

16.

Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer [Internet].

Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Jan 22.

17.

Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM.

Int J Cancer. 2015 Jun 15;136(12):2864-74. doi: 10.1002/ijc.29343. Epub 2014 Dec 3.

18.

Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina.

van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I.

Health Serv Res. 2015 Jun;50(3):768-89. doi: 10.1111/1475-6773.12246. Epub 2014 Oct 16.

19.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

20.

The human myotendinous junction: an ultrastructural and 3D analysis study.

Knudsen AB, Larsen M, Mackey AL, Hjort M, Hansen KK, Qvortrup K, Kjaer M, Krogsgaard MR.

Scand J Med Sci Sports. 2015 Feb;25(1):e116-23. doi: 10.1111/sms.12221. Epub 2014 Apr 10.

PMID:
24716465
21.

Secular trends in colon and rectal cancer relative survival.

Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D.

J Natl Cancer Inst. 2013 Dec 4;105(23):1806-13. doi: 10.1093/jnci/djt299. Epub 2013 Oct 30.

22.

Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.

Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM.

Ann Intern Med. 2012 Nov 6;157(9):611-20. doi: 10.7326/0003-4819-157-9-201211060-00005.

23.

Contribution of screening and survival differences to racial disparities in colorectal cancer rates.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):728-36. doi: 10.1158/1055-9965.EPI-12-0023. Epub 2012 Apr 18.

24.

How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis.

Haug U, Knudsen AB, Kuntz KM.

Int J Cancer. 2012 Nov 1;131(9):2094-102. doi: 10.1002/ijc.27463. Epub 2012 Mar 29.

25.

Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD.

Radiology. 2011 Nov;261(2):487-98. doi: 10.1148/radiol.11102411. Epub 2011 Aug 3.

26.

Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review.

Haug U, Knudsen AB, Brenner H, Kuntz KM.

Expert Rev Mol Diagn. 2011 Jul;11(6):605-16. doi: 10.1586/erm.11.41. Review.

PMID:
21745014
27.

Clarifying differences in natural history between models of screening: the case of colorectal cancer.

van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM.

Med Decis Making. 2011 Jul-Aug;31(4):540-9. doi: 10.1177/0272989X11408915. Epub 2011 Jun 14.

28.

A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression.

Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG.

Med Decis Making. 2011 Jul-Aug;31(4):530-9. doi: 10.1177/0272989X11408730. Epub 2011 Jun 14.

29.

Cost-effectiveness of colorectal cancer screening.

Lansdorp-Vogelaar I, Knudsen AB, Brenner H.

Epidemiol Rev. 2011;33:88-100. doi: 10.1093/epirev/mxr004. Epub 2011 Jun 1. Review.

30.

Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia.

Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H.

Br J Cancer. 2011 May 24;104(11):1779-85. doi: 10.1038/bjc.2011.160. Epub 2011 May 10.

31.

Computer disease simulation models: integrating evidence for health policy.

Rutter CM, Knudsen AB, Pandharipande PV.

Acad Radiol. 2011 Sep;18(9):1077-86. doi: 10.1016/j.acra.2011.02.004. Epub 2011 Mar 23. Review.

32.

Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis.

Berrington de González A, Kim KP, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Smith-Bindman R, Yee J, Kuntz KM, van Ballegooijen M, Zauber AG, Berg CD.

AJR Am J Roentgenol. 2011 Apr;196(4):816-23. doi: 10.2214/AJR.10.4907.

33.

Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy.

Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H.

Gastrointest Endosc. 2011 Mar;73(3):435-443.e5. doi: 10.1016/j.gie.2010.12.005.

PMID:
21353840
34.

Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M.

Ann Intern Med. 2010 Sep 21;153(6):368-77. doi: 10.7326/0003-4819-153-6-201009210-00004.

35.

Cost-effectiveness of colorectal cancer screening - an overview.

Lansdorp-Vogelaar I, Knudsen AB, Brenner H.

Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):439-49. doi: 10.1016/j.bpg.2010.04.004.

37.

Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG.

J Natl Cancer Inst. 2010 Aug 18;102(16):1238-52. doi: 10.1093/jnci/djq242. Epub 2010 Jul 27.

38.

Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis.

Greenblatt WH, Hur C, Knudsen AB, Evans JA, Chung DC, Gazelle GS.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2677-84. doi: 10.1158/1055-9965.EPI-09-0153. Epub 2009 Sep 29.

39.

Calibration methods used in cancer simulation models and suggested reporting guidelines.

Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS.

Pharmacoeconomics. 2009;27(7):533-45. doi: 10.2165/11314830-000000000-00000. Review.

40.

Assessing the comparative effectiveness of a diagnostic technology: CT colonography.

Pearson SD, Knudsen AB, Scherer RW, Weissberg J, Gazelle GS.

Health Aff (Millwood). 2008 Nov-Dec;27(6):1503-14. doi: 10.1377/hlthaff.27.6.1503.

PMID:
18997205
41.

Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM.

Ann Intern Med. 2008 Nov 4;149(9):659-69. Epub 2008 Oct 6.

42.

Use of modeling to evaluate the cost-effectiveness of cancer screening programs.

Knudsen AB, McMahon PM, Gazelle GS.

J Clin Oncol. 2007 Jan 10;25(2):203-8. Review.

PMID:
17210941
43.

Occurrence and spread in Italy of Aedes albopictus, with implications for its introduction into other parts of Europe.

Knudsen AB, Romi R, Majori G.

J Am Mosq Control Assoc. 1996 Jun;12(2 Pt 1):177-83.

PMID:
8827590
44.

Global distribution and continuing spread of Aedes albopictus.

Knudsen AB.

Parassitologia. 1995 Dec;37(2-3):91-7. Review.

PMID:
8778670
46.
47.
48.

Saint Lucia revisited.

Bos R, Février M, Knudsen AB.

Parasitol Today. 1988 Oct;4(10):295-8.

PMID:
15463009
49.

Potential for organophosphate resistance in Aedes aegypti (Diptera: Culicidae) in the Caribbean area and neighboring countries.

Georghiou GP, Wirth M, Tran H, Saume F, Knudsen AB.

J Med Entomol. 1987 May;24(3):290-4. No abstract available.

PMID:
3585923

Supplemental Content

Loading ...
Support Center